The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer’s disease

Written by Ruth MacLeod, Ellin-Kristina Hillert, Ryan T Cameron & George S Baillie

Alzheimer’s disease (AD) is the most common form of dementia in the elderly and its prevalence is set to increase rapidly in coming decades. However, there are as yet no available drugs that can halt or even stabilize disease progression. One of the main pathological features of AD is the presence in the brain of senile plaques mainly composed of aggregated β amyloid (Aβ), a derivative of the longer amyloid precursor protein (APP). The amyloid hypothesis proposes that the accumulation of Aβ within neural tissue is the initial event that triggers the disease. Here we review research efforts that have...

To view this content, please register now for access

It's completely free